HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

Table 4 Impact of HER4 expression on the overall survival (OS) and disease-free survival (DFS) in tamoxifen-treated patients stratified by menopausal status

Strata	Predictor	OS				DFS
Strata	Predictor	HR	95% CI		p value	HR	95% CI		p value
Premenopausal (< 46 years)	HER4 continuous	1.06	0.59	1.89	0.845	0.77	0.43	1.38	0.380
Premenopausal (< 46 years)	HER4 ≥ 1 (ref. HER4 < 1)	1.51	0.25	9.01	0.655	0.56	0.15	2.03	0.377
Postmenopausal (≥ 46 years	HER4 continuous	1.43	1.09	1.86	0.009	1.81	1.25	2.63	0.002
Postmenopausal (≥ 46 years	HER4 ≥ 1 (ref. HER4 < 1)	4.98	1.32	18.80	0.018	2.94	0.96	9.00	0.059

ISSN: 1465-542X